Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.

The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

Cell and gene therapies (CGTs) have immense potential, but there are considerable challenges with logistics and storage that must be thoroughly understood and managed.

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

Some British people are turning to unregulated weight loss medications sold online as drug prices climb and prescription waits lengthen.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.

The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial.